Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 8 of 15
Jun 3, 2026This article explores how adopting a comprehensive identity strategy can improve data attribution accuracy, strengthen interoperability among healthcare entities, and ultimately support the effectiveness of value-based care initiatives.
Jun 3, 2026In a significant move for real-world data utilization in drug research, Novellia's platform aims to improve healthcare datasets by sourcing data directly from patients. The recent funding round underscores the growing importance of patient-centric data aggregation in healthcare innovation.
Jun 3, 2026The fresh capital infusion aims to fuel development and scaling of Ilant Health's approach to treating obesity, a condition with significant global health implications. This investment round reflects growing interest in innovative therapies and digital health platforms targeting metabolic disorders.
Jun 2, 2026The considerable funding raised by NewLimit underscores growing investor confidence in longevity therapeutics. The company is gearing up for a clinical trial that could pave the way for novel approaches to treating age-related liver diseases.
Jun 1, 2026Oral health is increasingly recognized as intrinsic to overall health, especially in pregnant women. This article explores the compelling reasons why obstetricians and gynecologists, public health agencies, and insurance plans should intensify their focus on oral health to reduce pregnancy complications such as pre-eclampsia.
Jun 1, 2026The glucose monitoring technology initially designed for diabetes care is increasingly being adapted for broader health applications. Signos’ recent $20 million investment round underscores the expanding role of CGM in personalized health, especially focusing on weight management through real-time glucose data and lifestyle recommendations.
May 31, 2026The health tech sector continues its trajectory of growth with major funding announcements. These investments will support the development of transformative technologies poised to enhance care delivery, improve patient outcomes, and drive healthcare efficiency worldwide.
May 30, 2026A comprehensive overview of the key executive hires, exits, and workforce reductions during May reveals evolving trends in healthcare management. This shift underscores the dynamic nature of healthcare as it adjusts to new business challenges, innovation demands, and market pressures.
May 28, 2026In a substantial financial commitment, Blackstone Life Sciences will provide up to $1.3 billion in non-dilutive capital to Apogee Therapeutics. This infusion is aimed at advancing clinical development of Apogee’s long-acting antibody therapy with potential applications beyond eczema, including asthma and eosinophilic esophagitis.
May 27, 2026Germany has proven its ability to nurture biotech winners thanks to robust scientific research and early support mechanisms. However, two venture capitalists emphasize that Europe's biotech ecosystem requires substantial improvements in financing depth, investor backing across borders, and regulatory reforms to enable companies to scale domestically and internationally.
May 25, 2026Precision medicine, the tailoring of medical care to individual genomic profiles, has rapidly expanded across health systems. Yet operational and financial hurdles continue to complicate its broader integration into routine clinical practice, signaling that the next frontier in precision medicine is effective execution rather than scientific discovery.
May 24, 2026In an era where healthcare costs and operational challenges continue to rise, payers are compelled to adopt smarter engagement strategies. By integrating unified technological infrastructures, payers can enhance member experiences and streamline operations. This analysis examines current trends and effective tactics that empower payers to maximize growth while managing limited resources.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.